Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts

Molecular Cancer Therapeutics

Volumn 7, Issue 10, 2008, Pages 3223-3236

  Sarup, Jay ^a   Jin, Pei ^a   Turin, Lisa ^a   Bai, Xiaomei ^a   Beryt, Malgorzata ^a   Brdlik, Cathleen ^a   Higaki, Jeffrey N ^a   Jorgensen, Brett ^a   Lau, Francis W ^a   Lindley, Peter ^a   Liu, Jim ^a   Ni, Irene ^a   Rozzelle, James ^a   Kumari, Rajendra ^b   Watson, Susan A ^b   Zhang, Juan ^a   Shepard, H Michael ^a  

^a Receptor BioLogix Inc   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EUROPIUM; GEFITINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; HERMODULIN; HETERODIMER; HOMODIMER; IMATINIB; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; LANTHANIDE; LAPATINIB; LIGAND; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; RB200; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR; MONOCLONAL ANTIBODY; PHOSPHOSERINE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL PROLIFERATION; CONTROLLED STUDY; CROSS LINKING; DRUG INHIBITION; DRUG POTENTIATION; EMBRYO; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DIMERIZATION; DRUG EFFECT; DRUG SCREENING; METABOLISM; MOLECULAR CLONING; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CLONING, MOLECULAR; DIMERIZATION; DRUG SYNERGISM; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; LIGANDS; MICE; NEUREGULIN-1; PHOSPHOSERINE; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 55749092281     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-2151     Document Type: Article

References (37)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
2. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
3. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85.
4. Stein RA, Staros JV. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evol Biol 2006;6:79.
5. Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S. Heregulin induces tyrosine phosphorylation of HER4/ p180erbB4. Nature 1993;366:473-5.
6. Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem 1996;271:30897-903.
7. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
8. Kraus S, Benard O, Naor Z, Seger R. c-Src is activated by the epidermal growth factor receptor in a pathway that mediates JNK and ERK activation by gonadotropin-releasing hormone in COS7 cells. J Biol Chem 2003;278:32618-30.
9. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL III. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 1994;91:8132-6.
10. Britten CD. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 2004;3:1335-42.
11. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
12. Stove C, Bracke M. Roles for neuregulins in human cancer. Clin Exp Metastasis 2004;21:665-84.
13. Tanaka Y, Miyamoto S, Suzuki SO, et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005;11:4783-92.
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
15. Bianchi S, Palli D, Falchetti M, et al. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol 2006;206:702-8.
16. Boyd B, Bozzo J, Castaner J. Lapatinib. Drugs Fut 2005;30:1225-39.
17. Weiner LM, Borghaei H. Targeted therapies in solid tumors: monoclonal antibodies and small molecules. Hum Antibodies 2006;15:103-11.
18. Pegram MD. Molecular determinants of trastuzumab response/ resistance. AACR Education Book 2005:155-9.
19. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
20. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
21. Karamouzis MV, Badra FA, Papavassiliou AG. Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 2007;39:851-6.
22. Ishikawa N, Daigo Y, Takano A, et al. Increases of amphiregulin and transformingg rowth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 2005;65:9176-84.
23. Zhou BB, Peyton M, He B, et al. Targeting ADAM-mediated ligand cleavage to inhibit and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006;10:39-50.
24. Sugarman BJ, Lewis GD, Eessalu TE, Aggarwal BB, Shepard HM. Effects of growth factors on the antiproliferative activity of tumor necrosis factors. Cancer Res 1987;47:780-6.
25. Burgess AW, Cho HS, Eigenbrot C, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12:541-52.
26. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM. Sheddinglig ht on ADAM metalloproteinases. Trends Biochem Sci 2005;30:413-22.
27. Schafer B, Marg B, Gschwind A, Ullrich A. Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 2004;279:47929-38.
28. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-91.
29. Willmarth NE, Ethier SP. Autocrine and juxtacrine effects of amphiregulin on the proliferative, invasive, and migratory properties of normal and neoplastic human mammary epithelial cells. J Biol Chem 2006;281:37728-37.
30. Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. Combininglapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressingbreas t cancer cells. Oncogene 2005;24:6213-21.
31. Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem 1993;268:11134-42.
32. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
33. Fitzpatrick VD, Pisacane PI, Vandlen RL, Sliwkowski MX. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett 1998;431:102-6.
34. Jones JT, Akita RW, Sliwkowski MX. Bindingsp ecificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227-31.
35. Domagala T, Konstantopoulos N, Smyth F, et al. Stoichiometry, kinetic and bindinganalysis of the interaction between epidermal growth factor (EGF) and the extracellular domain of the EGF receptor. Growth Factors 2000;18:11-29.
36. Lemmon MA, Bu Z, Ladbury JE, et al. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J 1997;16:281-94.
37. Scallon B, Cai A, Solowski N, et al. Bindingan d functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.